CanPei (6919) Receives Taiwan FDA Approval for Phase 2 Asia-Pacific Clinical Trial of New Drug CBL-514 for Abdominal Fat Reduction
NQ Score
3/100
N1 Content Completeness
4
AI Summary (NQ-processed)
On May 19, 2026, CanPei* announced it has received approval from the Taiwan Food and Drug Administration (TFDA) to conduct a Phase 2 Asia-Pacific clinical trial (CBL-0206) for its new injectable drug, CBL-514, aimed at reducing subcutaneous abdominal fat. The trial will enroll approximately 250 subjects in Taiwan and Australia to gather safety and efficacy data on Asian populations, supporting future New Drug Applications (NDA) and market promotion.